Skip to main content

Table 1 Characteristics of the study population

From: Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer

  Study cohort (n = 99)
Age (years) (mean (median:IQR)) 65.9 (66 : 62.0-69.0)
PSA (ng/mL) (mean (median:IQR)) 46.1 (7.4 : 5.5-11.6)a
Family history of PCa (no-yes-NA) 43.4%-13.1%-42.4%
First biopsy (n (%)) 91 (92.0%)
Prostate volume (mean (median:IQR)) 55.5 (49: 36-72)
PSA density (ng/mL x cc-1) (mean (median : IQR)) 0.89 (0.15 : 0.09-0.27)
DRE (abnormal) (%) 54 (54.5%)
PCa diagnosis (n (%)) 54 (54.5%)
 Gleason score ≤6 (n (%)) 17 (31.5%)
 Gleason score 7 (n (%)) 18 (33.3%)
 Gleason score 8-10 (n (%)) 19 (35.2%)
  1. DRE digital rectal examination, IQR inter quartile range, NA not applicable, PCa prostate cancer, PSA prostate-specific antigen
  2. aFour men had serum PSA values of more than 100 ng/mL. Without these outliers the average PSA value was 12.1 ng/mL